

Oncology novel active substances launched in 2022

Drug	Indication
Carvykti (ciltacabtagene autoleucl)	Relapsed or refractory multiple myeloma
Elahere (mirvetuximab soravtansine)	FR α positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
Imjudo (tremelimumab)	Hepatocellular carcinoma
Kimmtrak (tebentafusp)	Unresectable or metastatic uveal melanoma
Krazati (adagrasib)	Non-small cell lung cancer (NSCLC)
Opdualag (nivolumab + relatlimab)	Unresectable or metastatic melanoma
Pluvicto (lutetium (177Lu) vipivotide tetraxetan)	Prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)
Rezlidhia (olutasidenib)	Acute myeloid leukemia
Tecvayli (teclistamab)	Relapsed or refractory multiple myeloma
Vonjo (pacritinib)	Myelofibrosis

Source: IQVIA Institute for Human Data Science